TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05083000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
Study: NCT06217107

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Micro-learning content
Description: This is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x app
Description: The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
Study: NCT05571371

Intervention type: OTHER
Intervention: Measuring inflammatory serum biomarkers
Description: Measuring inflammatory serum biomarkers
Study: NCT06217107

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health360x app
Description: The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally congruent coaching
Description: The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally congruent coaching
Description: The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
Study: NCT06357403

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-factor Xa activity calibrated for enoxaparin
Description: Anti-factor Xa activity calibrated for enoxaparin
Study: NCT04752163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Given PO
Study: NCT04937972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 Combined With Fluazopalil
Description: SHR-1701 +fluzoparib
Study: NCT05361824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injection
Description: dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
Study: NCT05660460

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometry
Description: The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
Study: NCT06182943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture combined with surrounding acupuncture
Description: electroacupuncture combined with surrounding acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: sham electroacupuncture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ice compress combined with brake rest
Description: ice compress combined with brake rest
Study: NCT06160232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (high dose)
Description: Psilocybin-assisted therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active placebo (low dose of psilocybin)
Description: Placebo-assisted therapy
Study: NCT05783206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR 19 ®
Description: MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
Study: NCT05222828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbocaine Injectable Product
Description: One injection per patient
Study: NCT03796507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
Study: NCT06036277

Intervention type: OTHER
Intervention: General data
Description: General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight

Intervention type: OTHER
Intervention: General data
Description: General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight

Intervention type: OTHER
Intervention: Other data
Description: Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.

Intervention type: OTHER
Intervention: Other data
Description: Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
Study: NCT05356416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses.
Study: NCT03867032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training
Description: Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
Study: NCT05611632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-cancer early detection test (Galleri test)
Description: Blood collection and multi cancer early detection testing with return of positive test results.
Study: NCT05966597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written persuasive leaflet
Description: Additional written behavioural persuasive technique leaflet and a standard referral leaflet provided at the end of the home-based health screening.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard referral leaflet
Description: Standard referral leaflet provided at the end of the home-based health screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard referral leaflet
Description: Standard referral leaflet provided at the end of the home-based health screening.
Study: NCT05806437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sideremil vita cp
Description: assunzione per 30 giorni dell'integratore

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sideremil vita cp
Description: assunzione per 30 giorni dell'integratore
Study: NCT04912778

Intervention type: OTHER
Intervention: Filling in an online survey
Description: Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
Study: NCT04711785

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent exercise program
Description: The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week.
Study: NCT04508166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma-Hydroxybutyrate
Description: Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Model Trauma Film
Description: Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Model Trauma Film
Description: Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Model Trauma Film
Description: Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
Study: NCT06124365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock wave therapy and core stability exercises
Description: 20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stability exercises only
Description: 20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
Study: NCT06292962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcutaneous vagal nerve stimulation (tVNS)
Description: The device is used stimulate the vagus nerve
Study: NCT06251063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational resource
Description: The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations.~The materials will address the following content areas:~* Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH.~* Describe specific social challenges that commonly affect children with CDH.~* Explain the impact that medications typically prescribed for CDH may have on social relationship health.~* Help families advocate for their child's social needs at school.~* Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings.~* Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician.~* Provide a list of programming which offers children both structured and unstructured opportunities for social engagement
Study: NCT06292962

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham device that does not stimulate the vagus nerve
Study: NCT04907526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mononuclear cells
Description: Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
Study: NCT06046950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment target DAS28CRP-LDA
Description: Aiming for DAS28CRP-low disease activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment target SDAI-remission
Description: Aiming for SDAI-remission
Study: NCT06101654

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: Devices (4) were placed on the finger and the fingertip of both index fingers. Blood samples were taken at each stable level of oxygenation.
Study: NCT06544304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA
Description: PMMA 30%
Study: NCT05147077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group.
Study: NCT05518435

Intervention type: OTHER
Intervention: None, observational study
Description: The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Intervention type: OTHER
Intervention: None, observational study
Description: The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Intervention type: OTHER
Intervention: None, observational study
Description: The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
Study: NCT06547580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based PFMT
Description: Under the supervision of an experienced physiotherapist, group-based pelvic floor muscle training was applied for 12 weeks, 2 sessions per week, 30-45 minutes each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized PFMT
Description: Under the supervision of an experienced physiotherapist, individualized pelvic floor muscle training was performed using the Emg Biofeedback device, 2 sessions a week, 30-45 minutes each session, in 12 weeks.
Study: NCT04605510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Cervical Joint Mobilization
Description: It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
Study: NCT03935269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cereset Research Wearable
Description: CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress management therapy
Description: Undergo Cereset research office intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies